Virginia Byers Kraus1, Jamie E Collins2, David Hargrove3, Elena Losina2, Michael Nevitt4, Jeffrey N Katz4, Susanne X Wang5, Linda J Sandell6, Steven C Hoffmann7, David J Hunter8. 1. Duke Molecular Physiology Institute and Division of Rheumatology, Duke University School of Medicine, Durham, North Carolina, USA. 2. Brigham and Women's Hospital, Boston, Massachusetts, USA. 3. LabCorp Clinical Trials, San Leandro, California, USA. 4. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA. 5. AbbVie, North Chicago, Illinois, USA. 6. Department of Orthopaedic Surgery, Musculoskeletal Research Center, Washington University in St. Louis, St Louis, Missouri, USA. 7. Foundation for the National Institutes of Health, Bethesda, Maryland, USA. 8. Rheumatology Department, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, New South Wales, Australia.
Abstract
OBJECTIVE: To investigate a targeted set of biochemical biomarkers as predictors of clinically relevant osteoarthritis (OA) progression. METHODS: Eighteen biomarkers were measured at baseline, 12 months (M) and 24 M in serum (s) and/or urine (u) of cases (n=194) from the OA initiative cohort with knee OA and radiographic and persistent pain worsening from 24 to 48 M and controls (n=406) not meeting both end point criteria. Primary analyses used multivariable regression models to evaluate the association between biomarkers (baseline and time-integrated concentrations (TICs) over 12 and 24 M, transposed to z values) and case status, adjusted for age, sex, body mass index, race, baseline radiographic joint space width, Kellgren-Lawrence grade, pain and pain medication use. For biomarkers with adjusted p<0.1, the c-statistic (area under the curve (AUC)), net reclassification index and the integrated discrimination improvement index were used to further select for hierarchical multivariable discriminative analysis and to determine the most predictive and parsimonious model. RESULTS: The 24 M TIC of eight biomarkers significantly predicted case status (ORs per 1 SD change in biomarker): sCTXI 1.28, sHA 1.22, sNTXI 1.25, uC2C-HUSA 1.27, uCTXII, 1.37, uNTXI 1.29, uCTXIα 1.32, uCTXIβ 1.27. 24 M TIC of uCTXII (1.47-1.72) and uC2C-Human Urine Sandwich Assay (HUSA) (1.36-1.50) both predicted individual group status (pain worsening, joint space loss and their combination). The most predictive and parsimonious combinatorial model for case status consisted of 24 M TIC uCTXII, sHA and sNTXI (AUC 0.667 adjusted). Baseline uCTXII and uCTXIα both significantly predicted case status (OR 1.29 and 1.20, respectively). CONCLUSIONS: Several systemic candidate biomarkers hold promise as predictors of pain and structural worsening of OA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: To investigate a targeted set of biochemical biomarkers as predictors of clinically relevant osteoarthritis (OA) progression. METHODS: Eighteen biomarkers were measured at baseline, 12 months (M) and 24 M in serum (s) and/or urine (u) of cases (n=194) from the OA initiative cohort with knee OA and radiographic and persistent pain worsening from 24 to 48 M and controls (n=406) not meeting both end point criteria. Primary analyses used multivariable regression models to evaluate the association between biomarkers (baseline and time-integrated concentrations (TICs) over 12 and 24 M, transposed to z values) and case status, adjusted for age, sex, body mass index, race, baseline radiographic joint space width, Kellgren-Lawrence grade, pain and pain medication use. For biomarkers with adjusted p<0.1, the c-statistic (area under the curve (AUC)), net reclassification index and the integrated discrimination improvement index were used to further select for hierarchical multivariable discriminative analysis and to determine the most predictive and parsimonious model. RESULTS: The 24 M TIC of eight biomarkers significantly predicted case status (ORs per 1 SD change in biomarker): sCTXI 1.28, sHA 1.22, sNTXI 1.25, uC2C-HUSA 1.27, uCTXII, 1.37, uNTXI 1.29, uCTXIα 1.32, uCTXIβ 1.27. 24 M TIC of uCTXII (1.47-1.72) and uC2C-Human Urine Sandwich Assay (HUSA) (1.36-1.50) both predicted individual group status (pain worsening, joint space loss and their combination). The most predictive and parsimonious combinatorial model for case status consisted of 24 M TIC uCTXII, sHA and sNTXI (AUC 0.667 adjusted). Baseline uCTXII and uCTXIα both significantly predicted case status (OR 1.29 and 1.20, respectively). CONCLUSIONS: Several systemic candidate biomarkers hold promise as predictors of pain and structural worsening of OA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: B Mazières; P Garnero; A Guéguen; M Abbal; L Berdah; M Lequesne; M Nguyen; J-P Salles; E Vignon; M Dougados Journal: Ann Rheum Dis Date: 2005-12-01 Impact factor: 19.103
Authors: David Hunter; Michael Nevitt; John Lynch; Virginia Byers Kraus; Jeffrey N Katz; Jamie E Collins; Mike Bowes; Ali Guermazi; Frank W Roemer; Elena Losina Journal: Ann Rheum Dis Date: 2015-10-19 Impact factor: 19.103
Authors: Anant Narayan Bhatt; Rohit Mathur; Abdullah Farooque; Amit Verma; B S Dwarakanath Journal: Indian J Med Res Date: 2010-08 Impact factor: 2.375
Authors: Erik B Dam; Marco Loog; Claus Christiansen; Inger Byrjalsen; Jenny Folkesson; Mads Nielsen; Arish A Qazi; Paola C Pettersen; Patrick Garnero; Morten A Karsdal Journal: Arthritis Res Ther Date: 2009-07-24 Impact factor: 5.156
Authors: E Gineyts; J A Mo; A Ko; D B Henriksen; S P Curtis; B J Gertz; P Garnero; P D Delmas Journal: Ann Rheum Dis Date: 2004-07 Impact factor: 19.103
Authors: S Christgau; Y Henrotin; L B Tankó; L C Rovati; J Collette; O Bruyere; R Deroisy; J Y Reginster Journal: Clin Exp Rheumatol Date: 2004 Jan-Feb Impact factor: 4.473
Authors: R F Loeser; D P Beavers; A C Bay-Jensen; M A Karsdal; B J Nicklas; A Guermazi; D J Hunter; S P Messier Journal: Osteoarthritis Cartilage Date: 2017-07-27 Impact factor: 6.576
Authors: Svetlana Krasnokutsky; Charles Oshinsky; Mukundan Attur; Sisi Ma; Hua Zhou; Fangfei Zheng; Meng Chen; Jyoti Patel; Jonathan Samuels; Virginia C Pike; Ravinder Regatte; Jenny Bencardino; Leon Rybak; Steven Abramson; Michael H Pillinger Journal: Arthritis Rheumatol Date: 2017-04-28 Impact factor: 10.995
Authors: W Wirth; D J Hunter; M C Nevitt; L Sharma; C K Kwoh; C Ladel; F Eckstein Journal: Osteoarthritis Cartilage Date: 2017-08-31 Impact factor: 6.576
Authors: Jean-Yves L Reginster; Nigel K Arden; Ida K Haugen; Francois Rannou; Etienne Cavalier; Olivier Bruyère; Jaime Branco; Roland Chapurlat; Sabine Collaud Basset; Nasser M Al-Daghri; Elaine M Dennison; Gabriel Herrero-Beaumont; Andrea Laslop; Burkhard F Leeb; Stefania Maggi; Ouafa Mkinsi; Anton S Povzun; Daniel Prieto-Alhambra; Thierry Thomas; Daniel Uebelhart; Nicola Veronese; Cyrus Cooper Journal: Semin Arthritis Rheum Date: 2017-12-07 Impact factor: 5.532
Authors: Christopher L Mendias; Elizabeth R Sibilsky Enselman; Adam M Olszewski; Jonathan P Gumucio; Daniel L Edon; Maxwell A Konnaris; James E Carpenter; Tariq M Awan; Jon A Jacobson; Joel J Gagnier; Ariel L Barkan; Asheesh Bedi Journal: Am J Sports Med Date: 2020-05-26 Impact factor: 6.202
Authors: G B Joseph; M C Nevitt; C E McCulloch; J Neumann; J A Lynch; U Heilmeier; N E Lane; T M Link Journal: Osteoarthritis Cartilage Date: 2018-05-23 Impact factor: 6.576
Authors: L A Deveza; V B Kraus; J E Collins; A Guermazi; F W Roemer; M C Nevitt; D J Hunter Journal: Scand J Rheumatol Date: 2017-09-20 Impact factor: 3.641
Authors: Muhammad Farooq Rai; Linda J Sandell; Toby N Barrack; Lei Cai; Eric D Tycksen; Simon Y Tang; Matthew J Silva; Robert L Barrack Journal: Cartilage Date: 2018-09-03 Impact factor: 4.634